Belumosudil for lung scar prevention or treatment after transplant
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and were diagnosed with BOS after a stem cell transplant
- Your breathing test (and/or lung scan) shows specific pattern changes that match BOS, with set cutoff values
- You do not have a current uncontrolled lung infection (you may need recent tests like scans or cultures)
- You have enough blood and liver function (based on blood counts and AST/ALT limits)
- You have not had prior treatment specifically for BOS, and you’ve never taken belumosudil
- You are not enrolled with another investigational immune-suppressing drug; and you don’t have HIV or hepatitis B/C needing treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug LAM-001 can help people who have developed a condition called bronchiolitis obliterans syndrome (BOS) after a double lung transplant. BOS causes a slow decline in lung function, and this trial aims to see if LAM-001 can slow or stop that decline.
This study collects tiny airway samples during a planned bronchoscopy to better understand bronchiolitis obliterans (a long-term lung complication after transplant). Your samples may help researchers learn how the disease starts and changes over time.
This study checks new ways to measure breathing in children who had a stem cell transplant to better detect a lung condition called bronchiolitis obliterans syndrome. If you join, you’ll do breathing and imaging tests, and researchers will look for patterns that may help with diagnosis.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
This study tests a new medication called belumosudil to see how safe it is for people with chronic graft-versus-host disease (cGVHD). If you have had a stem cell transplant and still need treatment for cGVHD after trying other therapies, this trial may be an option.
This study tests a new medicine called belumosudil for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the body after a stem cell transplant. The trial compares belumosudil to the best available standard treatments to see if it works better at controlling the condition.
Hear when a new Bronchiolitis Obliterans Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.